| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2007-04-12 15:40:01 UTC |
|---|
| Update Date | 2022-03-07 02:49:29 UTC |
|---|
| HMDB ID | HMDB0005844 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | 8-isoprostaglandin E2 |
|---|
| Description | 8-isoprostaglandin E2 is an isoprostane generated from the endoperoxide intermediate 8-iso-PGH2. Isoprostanes (IsoPs) are formed in vivo from the free radical-catalyzed peroxidation of arachidonate independent of cyclooxygenase (COX). Although the structures of these compounds are very similar to COX-derived prostaglandins (PGs), an important distinction between IsoPs and PGs is that IsoP bicycloendoperoxide intermediates contain side chains that are predominantly (>90%) oriented cis in relation to the prostane ring because the generation of these intermediates is favored kinetically. In contrast to other types of prostanoids, E2/D2-IsoPs are beta-hydroxyketone-containing compounds that can undergo reversible keto-enol tautomerization under both acidic and basic conditions, allowing rearrangement of the side chains that are initially cis to the more stable trans-configuration (PMID: 12746435 ). Dinoprostone is a naturally occurring prostaglandin E2 (PGE2) and the most common and most biologically active of the mammalian prostaglandins. It has important effects in labour and also stimulates osteoblasts to release factors which stimulate bone resorption by osteoclasts (a type of bone cell that removes bone tissue by removing the bone's mineralized matrix). PGE2 has been shown to increase vasodilation and cAMP production, to enhance the effects of bradykinin and histamine, to induce uterine contractions and to activate platelet aggregation. PGE2 is also responsible for maintaining the open passageway of the fetal ductus arteriosus; decreasing T-cell proliferation and lymphocyte migration and activating the secretion of IL-1alpha and IL-2. PGE2 exhibits both pro- and anti-inflammatory effects, particularly on dendritic cells (DC). Depending on the nature of maturation signals, PGE2 has different and sometimes opposite effects on DC biology. PGE2 exerts an inhibitory action, reducing the maturation of DC and their ability to present antigen. PGE2 has also been shown to stimulate DC and promote IL-12 production when given in combination with TNF-alpha. PGE2 is an environmentally bioactive substance. Its action is prolonged and sustained by other factors especially IL-10. It modulates the activities of professional DC by acting on their differentiation, maturation and their ability to secrete cytokines. PGE2 is a potent inducer of IL-10 in bone marrow-derived DC (BM-DC), and PGE2-induced IL-10 is a key regulator of the BM-DC pro-inflammatory phenotype. (PMID: 16978535 )Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
|---|
| Structure | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@H]1C\C=C/CCCC(O)=O InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16-,17+,19+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 7-[3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoic acid | ChEBI | | 8-Epi-pge2 | ChEBI | | 8-Iso-pge2 | ChEBI | | 7-[3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoate | Generator | | (5Z,8b,11a,13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1-Oate | HMDB | | (5Z,8b,11a,13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1-Oic acid | HMDB | | 8-Isoprostaglandin e2 | ChEBI |
|
|---|
| Chemical Formula | C20H32O5 |
|---|
| Average Molecular Weight | 352.4651 |
|---|
| Monoisotopic Molecular Weight | 352.224974134 |
|---|
| IUPAC Name | (5Z)-7-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid |
|---|
| Traditional Name | 8-Iso-PGE2 |
|---|
| CAS Registry Number | 27415-25-4 |
|---|
| SMILES | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@H]1C\C=C/CCCC(O)=O |
|---|
| InChI Identifier | InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16-,17+,19+/m0/s1 |
|---|
| InChI Key | XEYBRNLFEZDVAW-CLQOMRTCSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Fatty Acyls |
|---|
| Sub Class | Eicosanoids |
|---|
| Direct Parent | Prostaglandins and related compounds |
|---|
| Alternative Parents | |
|---|
| Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Hydroxy fatty acid
- Cyclopentanol
- Fatty acid
- Unsaturated fatty acid
- Cyclic alcohol
- Ketone
- Cyclic ketone
- Secondary alcohol
- Carboxylic acid
- Carboxylic acid derivative
- Monocarboxylic acid or derivatives
- Alcohol
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Organooxygen compound
- Carbonyl group
- Aliphatic homomonocyclic compound
|
|---|
| Molecular Framework | Aliphatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.67 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.6049 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.21 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 50.7 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2681.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 208.7 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 180.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 179.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 235.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 582.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 475.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 142.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1236.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 511.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1424.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 350.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 402.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 332.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 173.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 9.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 8-isoprostaglandin E2,1TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O)C(=O)C[C@H]1O)O[Si](C)(C)C | 2825.3 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,1TMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O)C(=O)C[C@H]1O[Si](C)(C)C | 2760.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,1TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O[Si](C)(C)C)C(=O)C[C@H]1O | 2777.3 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,1TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@@H]1C(C/C=C\CCCC(=O)O)=C(O[Si](C)(C)C)C[C@H]1O | 2792.8 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,1TMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O | 2715.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O[Si](C)(C)C)C(=O)C[C@H]1O)O[Si](C)(C)C | 2783.0 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O)C(=O)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2722.0 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O)=C(O[Si](C)(C)C)C[C@H]1O)O[Si](C)(C)C | 2827.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #4 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2726.3 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O[Si](C)(C)C)C(=O)C[C@H]1O[Si](C)(C)C | 2721.7 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@@H]1C(C/C=C\CCCC(=O)O)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C | 2793.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O | 2747.3 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #8 | CCCCC[C@H](O)/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O | 2787.4 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TMS,isomer #9 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2724.3 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O[Si](C)(C)C)C(=O)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2711.5 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O)O[Si](C)(C)C | 2800.8 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2734.4 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TMS,isomer #4 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2781.6 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TMS,isomer #5 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2743.2 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C | 2774.0 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TMS,isomer #7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2733.4 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2794.8 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2871.7 | Standard non polar | 33892256 | | 8-isoprostaglandin E2,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2843.1 | Standard polar | 33892256 | | 8-isoprostaglandin E2,4TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2769.5 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,4TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2714.3 | Standard non polar | 33892256 | | 8-isoprostaglandin E2,4TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2917.3 | Standard polar | 33892256 | | 8-isoprostaglandin E2,1TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O)C(=O)C[C@H]1O)O[Si](C)(C)C(C)(C)C | 3071.9 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,1TBDMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O)C(=O)C[C@H]1O[Si](C)(C)C(C)(C)C | 2962.4 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,1TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)C(=O)C[C@H]1O | 3031.5 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,1TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@@H]1C(C/C=C\CCCC(=O)O)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O | 3056.6 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,1TBDMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O | 2956.7 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)C(=O)C[C@H]1O)O[Si](C)(C)C(C)(C)C | 3289.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O)C(=O)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3207.8 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O)O[Si](C)(C)C(C)(C)C | 3290.5 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #4 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3207.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)C(=O)C[C@H]1O[Si](C)(C)C(C)(C)C | 3197.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@@H]1C(C/C=C\CCCC(=O)O)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C | 3236.4 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O | 3198.7 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #8 | CCCCC[C@H](O)/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O | 3275.5 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,2TBDMS,isomer #9 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3205.0 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1[C@H](C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)C(=O)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3438.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O)O[Si](C)(C)C(C)(C)C | 3520.4 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3460.0 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TBDMS,isomer #4 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3460.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TBDMS,isomer #5 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3450.1 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TBDMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C | 3464.0 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,3TBDMS,isomer #7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3450.9 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3648.3 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3490.1 | Standard non polar | 33892256 | | 8-isoprostaglandin E2,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3150.4 | Standard polar | 33892256 | | 8-isoprostaglandin E2,4TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3645.5 | Semi standard non polar | 33892256 | | 8-isoprostaglandin E2,4TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3215.8 | Standard non polar | 33892256 | | 8-isoprostaglandin E2,4TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3179.9 | Standard polar | 33892256 |
|
|---|